GHK-Cu and collagen-making cells
The cell count stayed steady while collagen synthesis rose. That makes a more interesting starting point than a catalogue of anti-aging ambitions.
Fibroblasts making collagen
The 1988 collagen-synthesis study used human fibroblasts in culture. GHK-Cu stimulated collagen synthesis beginning between 10⁻¹² and 10⁻¹¹ M, with the maximum at 10⁻⁹ M, independently of a change in cell number. Those are concentrations in a cell experiment.
That is a narrow result, and I appreciate the precision. It describes a change in the work a cell performs, and the unchanged cell count makes the interpretation more specific. A person’s wound also has blood supply, inflammation, microbes and mechanical strain to contend with. The dish isolates one piece of that activity.
GHK-Cu is glycyl-L-histidyl-L-lysine bound to copper(II), also called Copper Tripeptide-1. Both SPARC/osteonectin and collagen (type I) contain the GHK sequence, as described in the review of GHK and tissue remodeling. There is something satisfying about a fragment of the supporting material being investigated for effects on the cells that replenish it.
Matrix turnover
Collagen is only part of the extracellular matrix, the material surrounding cells. The tissue-remodeling review also describes effects on elastin, glycosaminoglycans and decorin, alongside enzymes that break down the matrix and the proteins that restrain those enzymes. A tissue has to remove material as well as make it.
That upkeep deserves more attention, I think. The word collagen is so attractive in skin claims that the clearing and reorganising work can disappear behind it. In the cell and animal literature reviewed here, GHK-Cu engages several sides of remodeling, including repair-cell recruitment and vessel-growth signals. I hesitate to judge a tissue by collagen production alone when remodeling involves all this other work.
Copper also changes the identity of the material being tested. Free GHK and GHK-Cu occur in this literature, and some gene-expression work uses GHK. The copper-bound form is required for particular matrix-enzyme effects. I check which preparation was tested before borrowing its result for the copper peptide.
Topical findings and penetration
The 2015 review of skin-regeneration research reports increased collagen production in 70% of women treated with topical GHK-Cu, versus 50% for vitamin C and 40% for retinoic acid in the comparison it describes. It also collects small topical studies reporting improvements in skin laxity, clarity, fine lines, wrinkle depth and density. The human trials are small, with study sizes in the current record ranging from n=13–71.
I give these results more weight for a skin question than the breadth of a gene list. They measured skin. Even so, getting a peptide to the relevant tissue remains a practical difficulty: the 2025 review of topical GHK identifies poor passage through the stratum corneum, the outer skin barrier, as a central delivery problem.
In a separate experiment using excised human skin, the measured substance was copper applied as GHK-Cu. Over 48 hours, 136.2 ± 17.5 µg/cm² of copper permeated dermatomed skin and 97 ± 6.6 µg/cm² remained as a dermal depot; the permeability coefficient was 2.43 ± 0.51 × 10⁻⁴ cm/h. These are laboratory measurements through prepared skin layers. They leave the clinical outcome of a particular cream to be tested.
Hair trial and gene data
In the 6-month randomized hair trial involving 45 men, the tested preparation combined 5-aminolevulinic acid with glycyl-histidyl-lysine peptide. Hair-count increases were 52.6 at the study’s 100 mg/mL concentration and 71.5 at 50 mg/mL, versus 9.6 with placebo (p<0.05). No adverse events were reported in any group. Credit goes to the tested combination; the trial cannot assign the gain to pure GHK-Cu.
The 2018 analysis of gene-expression data offers a much broader kind of result. It reports approximately 31.2% of human genes altered at a 50%-or-greater change threshold, with 59% of affected genes increased and 41% decreased. At that threshold, the count is on the order of 2,100 genes; the familiar “~4,000 genes” figure comes from broader-threshold extrapolations.
The big tally leaves me with questions. Which changes persist in living tissue, which alter proteins, and which improve a relevant outcome? A database signature and a hair count answer different questions. Neither warrants a general claim of human rejuvenation.
GHK-Cu irritation and formulation limits
Skincare communities describe firmer-feeling skin, softer lines and better hydration, alongside redness, itching, stinging, dryness and occasional breakouts. Some report darker spots; others describe a more even tone. These are anecdotal accounts, and their disagreement leaves both benefit and harm difficult to quantify. Injectable-use stories have still less human evidence behind them.
The topical-delivery review discusses formulation stability, including incompatibility with ascorbic acid and low-pH actives that can destabilize the copper complex. That is a chemical limitation of the preparation. It offers no basis for a personal mixing or application schedule here.
Topical Copper Tripeptide-1 is a legal cosmetic ingredient. Compounded injectable GHK-Cu has no FDA approval and requires a patient-specific prescription following clinical assessment; validated human pharmacokinetic data are lacking. The wider anti-aging and systemic claims draw heavily on cell, animal and database work, with much foundational literature concentrated among one investigator and colleagues. The proposed benefit list can wait. I want this cell activity reproduced in clearly defined tissue. Compare the BPC-157 experiments.